Building a New Kind of Biopharma Company
We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.
Our Story
Meet Our Leadership
We are led by experienced biopharma executives with exceptional track records of building strong, innovative and diverse teams across the healthcare industry.
Meet Our Leadership
See Our Pipeline
We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients.
See Our PipelineOur Advantage
Building a Different Kind of Biopharma Company
We have the right blend of experience along with a broad network of relationships across healthcare to acquire, develop and commercialize the most promising therapeutic programs to transform patients’ lives.
Search and Select the Best
We leverage the global network of our team and investors to identify promising assets using their cumulative development and commercial expertise.
Efficiently Build the Portfolio
We utilize our deep experience in business development to identify win-win licenses, partnerships, or acquisitions that enable rapid creation of ACELYRIN’s therapeutics portfolio.
Maximize Program Potential
We design and implement development programs aiming to reduce risks and accelerate timelines while maximizing the therapeutic and commercial potential.
Rapidly Assemble Teams and Resources
We can rapidly assemble teams and resources required for efficient execution of the development, regulatory, manufacturing, and commercial processes.
Latest Press Releases
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Press Release
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Read more ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Press Release
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Read more 